REGN News and Press, Regeneron Pharmaceuticals Inc. From 03/26/24

2024-03-26 13:15:05 ET RBC Capital analyst issues BUY recommendation for REGN on March 26, 2024 10:01AM ET. The previous analyst recommendation was Buy. REGN was trading at $958.6051 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...

2024-03-25 10:29:37 ET More on Regeneron Pharmaceuticals Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript) Regeneron Pharmaceuticals, Inc. (REGN) Barclays 26th Annual Global Healthcare Conference (Transcript) Regeneron P...

TARRYTOWN, N.Y., March 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued Complete Response Letters (CRLs) for the Biologics License Application (BLA) for odronextamab in relapsed/refractory (R/R)...

2024-03-25 02:07:51 ET Summary Sanofi has underperformed the U.S. stock market lately but now offers one of the smartest growth-at-a-reasonable-price setups in Big Pharma. Sanofi is best known for its patented drug Dupixent and numerous vaccines manufactured for global use, which ...

2024-03-22 12:40:30 ET Intellia Therapeutics ( NASDAQ: NTLA ) is opting out of an agreement with Regeneron Pharmaceuticals ( NASDAQ: REGN ) to co-develop a factor IX gene editing therapy for hemophilia A and B, the biotechnology firm disclosed in a filing on Friday.... ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is one of today's top gainers. The company's shares have moved 0.41% on the day to $971.98. Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The compa...

2024-03-13 13:05:07 ET Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference March 13, 2024 10:40 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Christopher Fenimore - Chief Financial Officer Conference ...

2024-03-13 10:15:02 ET Morgan Stanley analyst issues OVERWEIGHT recommendation for REGN on March 13, 2024 08:51AM ET. The previous analyst recommendation was Overweight. REGN was trading at $970.57 at issue of the analyst recommendation. The overall analyst consensus : B...

TARRYTOWN, N.Y. and WASHINGTON, D.C., March 12, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Society for Science (the Society) announced that Achyuta Rajaram, 17, of Exeter, NH, won the top award in the Regeneron Science Talent Searc...

2024-03-12 13:35:31 ET Regeneron Pharmaceuticals, Inc. (REGN) Barclays 26th Annual Global Healthcare Conference Transcript March 12, 2024, 11:15 AM ET Executives Chris Fenimore - Chief Financial Officer Ryan Crowe - Vice President, Investor Relations Analysts ...